TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10863071

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation
Number of subjects: 445

Group type: COMPARATOR
Intervention: Accelerated fractionation
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: RPA Class II (Accelerated hyperfractionation)
Number of subjects: 445

Group type: COMPARATOR
Intervention: RPA Class II (Accelerated fractionation)
Number of subjects: 445
Study: 9191629

Group type: EXPERIMENTAL
Intervention: Educational materials (medication booklet, behavioral health booklet, video)
Number of subjects: 108
Study: 1337161

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.5 micrograms/day) for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 31
Study: 3799228

Group type: EXPERIMENTAL
Intervention: Iopamiro
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 150
Study: 30699443

Group type: EXPERIMENTAL
Intervention: Mercurius corrosivus (Merc-c.) at potency levels 24x to 30x
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water controls (unsuccussed and succussed water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic negative control (SNC) experiments
Number of subjects: 0
Study: 28384657

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (4-drug oral regimen: daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (4-drug oral regimen)
Number of subjects: 108
Study: 25670360

Group type: EXPERIMENTAL
Intervention: Corn oil (CO)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extra-virgin olive oil (EVOO)
Number of subjects: 54
Study: 23404155

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy (LG) with D2 lymphadenectomy
Number of subjects: 204
Study: 21916354

Group type: EXPERIMENTAL
Intervention: Dentifrice formulated with silicas (test)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 125
Study: 19556076

Group type: EXPERIMENTAL
Intervention: Sensory re-education program (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No further treatment (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 16478755

Group type: COMPARATOR
Intervention: 300 mg l-dopa
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.25 mg bromocriptine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15598116

Group type: EXPERIMENTAL
Intervention: Thought suppression with low cognitive load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thought suppression with high cognitive load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 0
Study: 11157334

Group type: EXPERIMENTAL
Intervention: Moderate energy-restricted diet (WL group)
Number of subjects: 27
Study: 9771303

Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.02 mg kg‐1 (Group A, n = 25)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.004 mg kg‐1 (Group G, n = 27)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Physiological saline (Group P, n = 25)
Number of subjects: 77
Study: 7834593

Group type: EXPERIMENTAL
Intervention: Social skills training in the clinic only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of four sessions in the clinic, four sessions in real-life, and six follow-up sessions in the clinic
Number of subjects: 28

Group type: COMPARATOR
Intervention: Social skills training (both groups)
Number of subjects: 28
Study: 3401658

Group type: EXPERIMENTAL
Intervention: 1 g ampicillin and 80 mg gentamicin pre‐operatively
Number of subjects: 93

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 93
Study: 29263079

Group type: EXPERIMENTAL
Intervention: Real-time therapeutic drug monitoring (TDM) with same-day real-time dose adaptation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-of-care group (no real-time TDM)
Number of subjects: 40
Study: 26654125

Group type: EXPERIMENTAL
Intervention: Specialized immunonutrition (SIM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral nutrition supplement (ONS)
Number of subjects: 29
Study: 25232713

Group type: EXPERIMENTAL
Intervention: Flexible 19G needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flexible 25G needle
Number of subjects: 100
Study: 23047542

Group type: EXPERIMENTAL
Intervention: Preprandial insulin aspart (Asp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postprandial insulin glulisine (Glu)
Number of subjects: 12
Study: 22249875

Group type: EXPERIMENTAL
Intervention: Noninvasive acoustic stimulation and analysis
Number of subjects: 5
Study: 19111551

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 70
Study: 16967595

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid and dipyridamole (30‐325 mg daily and 200 mg twice daily)
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Acetylsalicylic acid only (30‐325 mg daily)
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid and dipyridamole
Number of subjects: 2739
Study: 15518751

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at doses of 0.5, 1, 1.5, and 2 g/day
Number of subjects: 46
Study: 11561938

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 14
Study: 9258756

Group type: EXPERIMENTAL
Intervention: Ground-Reaction Forces (GRF) exercise program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Joint-Reaction Forces (JRF) exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 39
Study: 7683447

Group type: EXPERIMENTAL
Intervention: 500 ml hydroxyethyl starch (HAES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 500 ml NaCl 0.9%
Number of subjects: 12
Study: 3128362

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nitrous oxide anaesthesia
Number of subjects: 36
Study: 29281798

Group type: EXPERIMENTAL
Intervention: NoCL (patients without unstable chondral lesions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NoCL
Number of subjects: 0

Group type: COMPARATOR
Intervention: CL‐noDeb (patients with unstable chondral lesions left in situ)
Number of subjects: 0
Study: 28763550

Group type: EXPERIMENTAL
Intervention: Contact aspiration (n=192)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Stent retriever (n=189)
Number of subjects: 381
Study: 25658671

Group type: EXPERIMENTAL
Intervention: Self-alert training (SAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23829776

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Balance
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Gait velocity
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 358
Study: 16884369

Group type: EXPERIMENTAL
Intervention: New cervical cell sampler (the implement)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cervex brush
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both devices (new implement and cervex brush)
Number of subjects: 200
Study: 12952113

Group type: EXPERIMENTAL
Intervention: Omalizumab (administered every 2 or 4 weeks for 52 weeks)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo (administered for 28 weeks)
Number of subjects: 309
Study: 10543320

Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus didanosine (ddI) at a dosage of 500 mg twice a day for at least 40 weeks
Number of subjects: 40
Study: 7776857

Group type: EXPERIMENTAL
Intervention: Interferon‐a2b subcutaneously three times weekly for 12 months (5 MU/m2 for 4 months and then 3 MU/m2 for a further 8 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interferon‐a2b
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 22
Study: 2406863

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7472292

Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (phenmetrazine)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (phentermine)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (mazindol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30249203

Group type: EXPERIMENTAL
Intervention: Self-management (includes educational components, SMBP, and self-titration of antihypertensive medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (includes educational components)
Number of subjects: 0
Study: 27481309

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Brodalumab 350 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Brodalumab 700 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 26769445

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioural Therapy (CBT‐E)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Maudsley Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 64
Study: 23846733

Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg twice daily for 16 weeks)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 148
Study: 21120259

Group type: EXPERIMENTAL
Intervention: Topical keratolytic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 18446414

Group type: EXPERIMENTAL
Intervention: Online tutorial covering 2 American Diabetes Association guidelines
Number of subjects: 91
Study: 15963095

Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 25 mg twice daily for 6 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12732397

Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyproterone acetate (CA)
Number of subjects: 30
Study: 10484952

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study: 7549168

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fentanyl 50 micrograms
Number of subjects: 69
Study: 1834765

Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose Lorazepam (LOR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neither drug (LOR or SCOP)
Number of subjects: 0
Study: 7296105

Group type: EXPERIMENTAL
Intervention: Instructional session on hearing tactics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not instructed)
Number of subjects: 0
Study: 31625806

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 698
Study: 30407275

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention led by parents (4 days/week for 24 weeks) including warm-up exercises, strengthening exercises, playground games, and interactive console games.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention led by parents
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 111
Study: 28403187

Group type: EXPERIMENTAL
Intervention: Advertisement of portable obstetric ultrasound by radio and word of mouth
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Women who had previously seen a traditional healer
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control arm with advertisement of antenatal care without mention of portable obstetric ultrasound
Number of subjects: 159
Study: 26551647

Group type: EXPERIMENTAL
Intervention: Collagen and alginate dressing (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alginate dressing alone (group B)
Number of subjects: 40
Study: 23842585

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 0
Study: 20692141

Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 37
Study: 18722088

Group type: EXPERIMENTAL
Intervention: Capture-mark-recapture (CMR; Horizon Estimate) statistical modeling
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Four large bibliographic databases (Medline, EMBASE, CINAHL, and EBM reviews)
Number of subjects: 1246
Study: 17584562

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg (medium dose)
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Nebivolol low dose (1.25 or 2.5 mg)
Number of subjects: 2061

Group type: COMPARATOR
Intervention: No nebivolol (placebo)
Number of subjects: 2061
Study: 15464768

Group type: EXPERIMENTAL
Intervention: High dose oxytocin (4.5 microm/min initially, increased by 4.5 microm/min every 30 min)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low dose oxytocin (1.5 microm/min initially, increased by 1.5 microm/min every 30 min)
Number of subjects: 200
Study: 11374116

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g of Cr and 5 g maltodextrin four times a day for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P) supplementation (5 g of maltodextrin four times a day for 5 days)
Number of subjects: 12
Study: 9648966

Group type: EXPERIMENTAL
Intervention: Positive pressure level set to suppress flow limitation (PFL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Positive pressure level set to eliminate only apnoea/hypopnoea and snoring (PAHS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group I (PFL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Group II (PAHS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Final maintenance of wakefulness test values
Number of subjects: 18
Study: 7863015

Group type: EXPERIMENTAL
Intervention: Moderate and high doses of alcohol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High doses of diazepam
Number of subjects: 108

Group type: COMPARATOR
Intervention: Baseline and treatment conditions
Number of subjects: 108
Study: 2678856

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 12
Study: 949688

Group type: EXPERIMENTAL
Intervention: Oral methotrexate plus radiation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate plus radiation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 123
Study: 30382188

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31079155

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer drug-eluting stents (BP-DES)
Number of subjects: 95610

Group type: COMPARATOR
Intervention: Permanent polymer drug-eluting stents (PP-DES)
Number of subjects: 95610
Study: 29094074

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) program during CCRT
Number of subjects: 12
Study: 25310347

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops four times daily for seven days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Artificial tears four times daily for seven days
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops
Number of subjects: 122

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 122
Study: 24015254

Group type: EXPERIMENTAL
Intervention: PTSS group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 21565956

Group type: EXPERIMENTAL
Intervention: Free oral hydration (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 10 mg of furosemide and infusion of 500 mL of saline solution starting 5 min after tracer injection (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral hydration with 500 mL of water (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 10 mg of furosemide and infusion of 250 mL of saline solution starting 30 min after (18)F‐FDG injection (Group D)
Number of subjects: 120
Study: 18651888

Group type: EXPERIMENTAL
Intervention: 2% xylocaine gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: KY jelly
Number of subjects: 90
Study: 15939523

Group type: COMPARATOR
Intervention: 100 mJ irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: 200 mJ irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: 300 mJ irradiation
Number of subjects: 21
Study: 12830441

Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional thrice-weekly HD (Control)
Number of subjects: 45
Study: 11296178

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily for five doses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for five doses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg q12h for nine doses
Number of subjects: 36
Study: 8779455

Group type: EXPERIMENTAL
Intervention: Piperacillin, 4 g, given intravenously approximately 30 minutes before ERCP
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo, given intravenously approximately 30 minutes before ERCP
Number of subjects: 551
Study: 1580924

Group type: EXPERIMENTAL
Intervention: Fructose (intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose (intervention)
Number of subjects: 0
Study: 4076529

Group type: EXPERIMENTAL
Intervention: Clocapramine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study: 29935582

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 47
Study: 26042657

Group type: EXPERIMENTAL
Intervention: Expectation Manipulation Intervention (EMI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard Medical Care
Number of subjects: 90

Group type: COMPARATOR
Intervention: Attention Control Group
Number of subjects: 90
Study: 24897168

Group type: EXPERIMENTAL
Intervention: IBS
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: FAPS
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: FAP
Number of subjects: 259
Study: 22187058

Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises (3-week rehabilitation program)
Number of subjects: 54
Study: 20525705

Group type: EXPERIMENTAL
Intervention: torasemide 5 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 18827916

Group type: EXPERIMENTAL
Intervention: Zofenopril (n=719)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Placebo (n=699)
Number of subjects: 1418
Study: 16238799

Group type: EXPERIMENTAL
Intervention: Standardized unmodified extract (Group A), maximum concentration of 308.5 mcg/mL, 11 injections total.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standardized modified allergen extract (Group B), maximum concentration of 2400 mcg/mL, 11 injections total.
Number of subjects: 23
Study: 11888774

Group type: EXPERIMENTAL
Intervention: Radical systematic lymphadenectomy (LA)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lymph node sampling (LS)
Number of subjects: 94
Study: 10434810

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg kg‐1
Number of subjects: 60
Study: 7892535

Group type: EXPERIMENTAL
Intervention: 10 ml/kg of Ringer solution (low dose crystalloid group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 ml/kg of Ringer solution (high dose crystalloid group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 ml/kg of Ringer solution with 10 ml/kg of hydroxi‐ethyl‐almidon solution (group C‐HEA)
Number of subjects: 36
Study: 2198295

Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 8
Study: 582393

Group type: EXPERIMENTAL
Intervention: 100 mg viloxazin
Number of subjects: 5
Study: 6896312

Group type: EXPERIMENTAL
Intervention: Coke (360 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tab (360 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Instant Maxwell House coffee (4.5 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Instant Kava coffee (4.5 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Instant Sanka coffee (4.5 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tea (4.25 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Beer (360 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Milk (360 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water
Number of subjects: 6
Study: 30792154

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Metformin (pooled analysis)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo (pooled analysis)
Number of subjects: 487
Study: 30565556

Group type: EXPERIMENTAL
Intervention: Group 'A' (discontinued treatment)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Group 'NA' (completed treatment)
Number of subjects: 155
Study: 26757749

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 24456145

Group type: EXPERIMENTAL
Intervention: IOP-lowering therapy
Number of subjects: 71